Brand-name GLP-1 medications — Ozempic, Wegovy, Mounjaro, Zepbound — are the specific, FDA-approved products manufactured by Novo Nordisk and Eli Lilly. Each has gone through the full FDA approval process: large-scale clinical trials, manufacturing standards specific to that exact formulation, and ongoing regulatory oversight. When you're prescribed a brand-name product, you're getting a standardized, mass-manufactured medication in a pre-filled pen, with a specific, unchanging formulation.
If you've researched GLP-1 medications for more than a few minutes, you've likely come across the terms “compounded” and “brand-name” — and possibly some confusion about what actually separates them. The distinction matters, both for your wallet and for understanding exactly what you're taking. Here's a clear, honest breakdown.
What “brand-name” means
What “compounded” means
Compounded medications are prepared by a licensed pharmacy rather than a large pharmaceutical manufacturer. Compounding itself is a long-standing, legitimate part of pharmacy practice — it's how patients get customized formulations when a commercial product doesn't fit their needs (different strengths, alternate delivery forms, or removal of an ingredient someone is allergic to, for example).
Compounded semaglutide and tirzepatide use the same active pharmaceutical ingredient as the brand-name versions, but are prepared by a compounding pharmacy rather than the original manufacturer, typically dispensed via multi-dose vial and syringe rather than a pre-filled pen.
Why compounded versions became so common
Between 2022 and late 2024, both semaglutide and tirzepatide were on the FDA's official drug shortage list. Federal law permits licensed pharmacies to compound versions of a drug that's in shortage, which is why compounded semaglutide and tirzepatide became widely available during that window — manufacturer supply simply couldn't meet demand.
That landscape has changed.The FDA has since declared both shortages resolved. Once a drug is off the shortage list, the legal basis for compounding it narrows considerably — compounding pharmacies can generally still prepare a version only for patients with a documented clinical need that the FDA-approved product can't meet, such as a verified allergy to an inactive ingredient in the brand-name pen, or a need for a different dose/strength combination that isn't commercially available. Broad, cost-based compounding — offering it simply because it's cheaper — is no longer the straightforward legal territory it was during the shortage years, and this area continues to see active regulatory and legal activity.
The real differences
Manufacturing and oversight
Brand-name medications are produced at large-scale FDA-regulated manufacturing facilities under strict, standardized processes. Compounded medications are prepared at the pharmacy level — quality depends heavily on that specific pharmacy's practices, licensing, and accreditation. This is a real difference, and it's why the credentials of the compounding pharmacy matter so much if you go this route: look for a licensed 503A pharmacy or FDA-registered 503B outsourcing facility, ideally with PCAB accreditation, and ask for a Certificate of Analysis confirming third-party testing of purity and concentration.
Formulation and delivery
Brand-name products come in pre-filled, pre-dosed pens. Compounded versions are typically dispensed in multi-dose vials, requiring the patient to draw up and measure each dose with a syringe. This gives compounded products more dosing flexibility (useful for micro-dosing or non-standard titration schedules some clinicians use) but also introduces more room for dosing error if instructions aren't followed carefully.
Cost
This has historically been the single biggest reason patients considered compounded options — often available at a meaningfully lower monthly cost than brand-name list pricing, particularly for patients without insurance coverage for weight management. That cost gap has narrowed somewhat as manufacturers have introduced their own lower-cost vial and self-pay programs, but a price difference often still exists.
Legal and regulatory status
Brand-name products carry the full weight of FDA approval — every batch is manufactured to an approved standard. Compounded products are not individually FDA-approved (compounding as a practice operates under a different regulatory framework), and, as noted above, are now legally appropriate only in narrower, documented-need circumstances than during the shortage years.
Questions worth asking if you're considering a compounded option
- What is the specific clinical justification for compounding in my case, and does it meet current regulatory criteria?
- Is the compounding pharmacy licensed and accredited, and can they provide a Certificate of Analysis?
- What exactly is in the formulation — is it single-ingredient, or does it include additives (like B12 or other ingredients sometimes bundled into compounded products)?
- How should I store and handle the medication, and how should I measure each dose correctly?
Which one is “better”?
There isn't a universal answer. Brand-name products offer standardization, full FDA approval, and the reassurance of large-scale manufacturing oversight — with a higher price tag and less dosing flexibility. Compounded products can offer meaningful cost savings and dosing flexibility, but their appropriateness now depends on meeting a genuine documented clinical need, and their quality depends heavily on the specific pharmacy behind them. The right choice depends on your individual clinical situation, insurance coverage, budget, and comfort level — and is a conversation worth having directly with a licensed provider rather than deciding on price alone.
Ready to compare providers?
Whether you're considering brand-name or compounded options, our provider comparison guide evaluates leading online telehealth programs by pricing, care quality, and transparency.
Compare GLP-1 Providers